Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | DGKA | P23743 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4067794 | 0.91 | TSHR (0.33) | ADRA2AADRA1AMAPTBLMTSHR | |
| SCHEMBL4075547 | 0.91 | LMNA (0.41) | ADRA2AADRA1AMAPTBLMTSHR | |
| SCHEMBL508579 | 0.90 | DGKA (0.41) | MAPTTSHRPOLBALDH1A1GAA | |
| SCHEMBL10105403 | 0.90 | TSHR (0.40) | MAPTTSHRPOLBALDH1A1DGKA | |
| SCHEMBL8528905 | 0.89 | TSHR (0.56) | ADRA2AADRA1AMAPTTSHRPOLB | |
| SCHEMBL9579525 | 0.87 | ALDH1A1 (0.30) | POLBALDH1A1 | |
| SCHEMBL8944030 | 0.85 | ACE (0.30) | — | |
| SCHEMBL9481223 | 0.85 | — | — | |
| SCHEMBL733969 | 0.85 | ALDH1A1 (0.48) | ADRA2AADRA1AMAPTTSHRALDH1A1 | |
| SCHEMBL13098016 | 0.85 | KDM4E (0.48) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5733907-A | Prodrugs of an inhibitor of HIV protease | MERCK & CO., INC. (US) | 1998-03-31 | — | — | US | disclosed |
| EP-0806957-A1 | COMBINATION THERAPY FOR HIV INFECTION USING THE HIV PROTEASE INHIBITOR INDINAVIR ADN THE REVERSE TRANSCRIPTASE INHIBITOR 3TC, OPTIONALLY TOGETHER WITH AZT, DDI OR DDC | Merck & Co., Inc. (US) | 1997-11-19 | — | — | EP | disclosed |
| EP-0767664-A2 | COMBINATION THERAPY FOR HIV INFECTION | MERCK & CO. INC. (US) | 1997-04-16 | — | — | EP | disclosed |
| EP-0729467-A1 | PRODRUGS OF AN INHIBITOR OF HIV PROTEASE | MERCK & CO. INC. (US) | 1996-09-04 | — | — | EP | disclosed |
| WO-1996023509-A1 | COMBINATION THERAPY FOR HIV INFECTION USING THE HIV PROTEASE INHIBITOR INDINAVIR AND THE REVERSE TRANSCRIPTASE INHIBITOR 3TC, OPTIONALLY TOGETHER WITH AZT, DDI OR DDC | MERCK & CO., INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| WO-1996000068-A2 | COMBINATION THERAPY FOR HIV INFECTION | MERCK & CO., INC. (US) | 1996-01-04 | — | — | WO | disclosed |
| WO-1995014016-A1 | PRODRUGS OF AN INHIBITOR OF HIV PROTEASE | MERCK & CO., INC. (US) | 1995-05-26 | — | — | WO | disclosed |